Microtest will also provide testing services to ImmusanT supporting its drug product manufacture, including method transfer activities, complete final product release testing, storage and stability.
ImmusanT raised $20m recently to progress the development of their technology, Nexvax2, to treat celiac disease.
Microtest Laboratories Project Management director Alex Mello said Microtest provides a faster and risk-minimizing alternative to subcontracting with a variety of providers at multiple locations.
"We deliver the flexibility, solutions, and problem-solving experience manufacturers must have to ensure the most expeditious release of their product," Mello added.